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Abstract
Introduction: Increased levels and activity of some matrix metalloproteinases (MMPs) are described in obesity-related vascular diseases. 
Factors that influence MMP blood concentration are still being investigated. This research aims to evaluate the concentration of most types 
of MMPs: collagenases (MMP-1, -3, -8, -13), matrilysin (MMP-7), gelatinase (MMP-9), and metalloelastase (MMP-12) in serum of women in 
reproductive age in relation with their body mass index (BMI), age, oestradiol, and progesterone concentrations. 
Material and methods: Blood samples were taken from 54 healthy reproductive-aged women with normal menstrual cycles. The weight 
and height of all women were measured, and body mass index (BMI) was calculated. Concentration of MMP-1, -3, -7, -8, -9, -12, and 
MMP-13 was evaluated using a Procarta Immunoassay Kit. Serum concentrations of oestradiol and progesterone were evaluated by im-
munochemiluminescence (32 in the proliferative and 20 in the secretory phase of menstrual cycle). The results of the study were statisti-
cally calculated using Pearson, Spearman, and Kruskal-Wallis tests.
Results: Positive correlation between MMP-7, -8, -9, -12, and -13 levels and BMI was demonstrated. Significantly higher concentrations of 
MMPs were found especially in obese women compared to women with normal BMI. In healthy, regularly menstruating premenopausal 
women, MMP levels did not correlate with oestradiol and progesterone concentrations. 
Conclusions: The results suggest that body mass can influence MMP serum concentration in women with regular menstrual cycles. 
(Endokrynol Pol 2019; 70 (1): 49–56)
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Streszczenie 
Wstęp: W doniesieniach opisuje się zwiększone stężenia i aktywności niektórych metaloproteinaz macierzy (MMP) w chorobach naczynio-
wych związanych z otyłością. Czynniki wpływające na stężenia MMP we krwi są wciąż tematem badań. Niniejsze badanie przeprowadzono 
w celu oceny stężeń większości typów MMP: kolagenaz (MMP-1, -3, -8, -13), matrylizyny (MMP-7), gelatynazy (MMP-9) i metaloelastazy 
(MMP-12) w surowicy kobiet w wieku rozrodczym w odniesieniu do wskaźnika masy ciała (body mass index, BMI) i wieku oraz stężeń 
estradiolu i progesteronu. 
Materiał i metody: Pobrano próbki krwi od 54 zdrowych kobiet w wieku rozrodczym z prawidłowym cyklem menstruacyjnym. U wszyst-
kich kobiet dokonano pomiaru masy ciała i wzrostu, a następnie obliczono wskaźnik masy ciała (BMI). Do oceny stężeń MMP-1, -3, -7, -8, 
-9, -12 i MMP-13 użyto zestawu Procarta Immunoassay. Stężenia estradiolu i progesteronu w surowicy mierzono metodą immunochemi-
luminescencji (32 w fazie proliferacyjnej i 20 w fazie wydzielniczej cyklu menstruacyjnego). Obliczenia statystyczne uzyskanych danych 
wykonano za pomocą testów Pearsona, Spearmana i Kruskala-Wallisa.
Wyniki: Wykazano dodatnią korelację między stężeniami MMP-7, -8, -9, -12 i -13 a wartością wskaźnika BMI. U kobiet otyłych stężenia 
MMP były istotnie wyższe niż u kobiet z prawidłowym wskaźnikiem BMI. W grupie zdrowych, regularnie miesiączkujących kobiet przed 
menopauzą stężenia MMP nie były skorelowane ze stężeniami estradiolu ani progesteronu. 
Wnioski: Wyniki badania wskazują, że masa ciała może wpływać na stężenie MMP w surowicy u kobiet z regularnymi cyklami menstru-
acyjnymi. (Endokrynol Pol 2019; 70 (1): 49–56)
Słowa kluczowe: MMP; otyłość; estradiol; progesteron
Introduction 
Overweight and obesity are major epidemiological 
problems in many countries, irrespective of their eco-
nomic position. Those conditions are accompanied by 
an increase in cardiovascular diseases, such as athero-
sclerosis, which is partially caused by remodelling of 
the extracellular matrix (ECM) [1]. Matrix metallopro-
teinases (MMPs) play a major role in this process, by 
regulating adipocyte development and remodelling [2].
Filip Dąbrowski; 1st Department of Obstetrics and Gynaecology, The Medical University of Warsaw, Starynkiewicza Sq. 1/3, 
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suggest that there is a relation between its level and the 
concentration of MMPs in the blood [12]. 
The second hormone that affects the synthesis and 
secretion of MMPs through its immunomodulatory 
effect is progesterone. Animal studies on mice showed 
a local anti-inflammatory effect of progesterone in the 
uterine cervix, due to the effect of this hormone on 
neutrophils and monocytes, both known to release 
MMP-9 [13]. However, there are no studies evaluating 
the correlation of those hormones’ serum concentration 
in obese women with MMP levels. 
In obese people, the most commonly researched 
MMPs in the blood are MMP-1, -2, and -9. The pres-
ent study investigated the activity of other MMPs as 
well. The results obtained from menstruating women 
were correlated with body weight as well as with 
oestradiol and progesterone concentrations, the two 
main hormones of which the concentrations change 
physiologically during the menstrual cycle. Describ-
ing dependencies between those factors can trigger 
further investigations on the vascular stability and 
pathomechanism of non-matrix disorders related to 
MMP concentrations [14]. 
The aim of the study was to evaluate the concen-
tration of representatives of most types of MMPs: 
collagenases (MMP-1, -3, -8, -13), matrilysin (MMP-7), 
gelatinase (MMP-9), and metalloelastase (MMP-12) in 
serum of women in reproductive age in relation to 
their body mass index (BMI), age, and oestradiol and 
progesterone concentrations. 
Material and methods
Baseline characteristics
The research was approved by the Bioethical Commit-
tee of the Medical University of Warsaw (KB/243/2012), 
and all participants signed informed consent before 
inclusion in the trial. Blood samples were taken from 
54 healthy women with normal menstrual periods 
aged 25–40 years. In 32 women blood samples were 
taken in the proliferative (day 4–6) and in 20 women 
in the secretory (day 21–22) phase of the cycle. Weight 
and height of all women were measured, and BMI was 
calculated. Population was divided into three sub-
groups: BMI-1 with BMI ≤ 24.9 kg/m2 (normoweight), 
BMI-2 with a BMI of 25–29.9 kg/m2 (overweight), and 
BMI-3 with a BMI ≥ 30 kg/m2 (obese). None of the 
participants was on hormonal treatment nor had they 
taken hormonal contraception prior to or during the 
research. Oestradiol and progesterone serum levels 
were assessed by immunochemiluminometric assay 
(ELISA, Elecsys, Cobase). As stated before samples 
were obtained from 32 patients in proliferative phase 
(day 4–6) and from 20 in secretory phase (day 21–22). 
MMPs are a family of protein enzymes. Their princi-
pal role is degradation of ECM at neutral pH. Produced 
on site in tissues, they are important for the functioning 
and homeostasis of the vascular bed. They also have 
an immunomodulatory effect through the cytokines, 
chemokines, and growth factors [3]. 
MMPs are classified in groups according to their 
structure and substrate specificity [4]: 
 — interstitial collagenases: collagenase-1 (MMP-1), col-
lagenase-2 (MMP-8), and collagenase-3 (MMP-13), 
which cleave native fibrillary collagen types I, II, 
and III;
 — stromelysins: stromelysin-1 (MMP-3), stromelysin-2 
(MMP-10), and stromelysin-3 (MMP-11), which de-
grade many components of basement membranes 
like fibronectin, laminin, and proteoglycan core 
protein;
 — matrylysin-1 (MMP-7) and (MMP-26), which de-
grade basement membrane;
 — gelatinases: gelatinase A (MMP-2) and gelatinase B 
(MMP-9), which degrade type IV collagen and col-
lagen denatured after initial cleavage of collagenase;
 — metalloelastase (MMP-12), also known as macro-
phage elastase.
MMPs play an important role not only in physi-
ological processes controlled by steroid hormones, 
such as cyclic degradation and renewal of human 
endometrium, embryo implantation, and trophoblast 
invasion, but also in the pathogenesis of benign and 
malignant tumours, formation of metastasis, and in im-
mune diseases [5]. MMPs are present in ECM, plasma, 
and other body fluids. Under physiological conditions, 
their concentration in the blood is low. 
Many factors have been reported that affect the 
production and activity of MMPs in the blood. It was 
found that high concentrations of circulating MMP-1 
are associated with atherosclerotic plaque inflamma-
tion in response to factors including stress, oxidised 
low-density lipoproteins (LDL), and proinflammatory 
cytokines. The increase of MMP-1 is positively corre-
lated with atherosclerotic lesions [6–8]. The increased 
levels of MMP-8 and MMP-9 in the blood of obese 
women are explained by the increment production by 
adipocytes [9]. However, there are high interindividual 
variations in the amount of MMP transcripts found 
both in fresh isolated human adipocytes and in in vitro 
tissue cultures. These data suggest that the synthesis of 
MMPs in adipocytes and their secretion into the blood 
remains under the control of still unknown modulating 
factors [10]. It seems that oestrogen may play a role in 
these processes, as it has been shown that oestrogens 
protect adipose tissue against oxidative stress [11]. 
Higher oestradiol levels during the menstrual cycle in 
overweight women, when compared to lean controls, 
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Data was metiliculously described in Table 1 according 
to BMI groups. Part of each sample was frozen and 
stored at –80°C. After thawing, the concentration of 
MMP-1, MMP-3, MMP-7, MMP-8, MMP-9, MMP-12, 
and MMP-13 were evaluated using a Procarta im-
munoassay kit (Affymatrix, CA, USA) in accordance 
with the manufacturer’s instruction. Multiplexes were 
run on a LABScanTM 100 platform (Luminex Corp., 
Austin, TX, USA) equipped with Luminex® 100 IS soft-
ware. Samples were incubated with antibody-coated 
microspheres, which bind to specific MMPs. Micro-
sphere-MMP complexes were washed and incubated 
with biotinylated MMP antibodies, which bind to 
MMPs present on the microspheres. A final incuba-
tion was performed in which phycoerythrin-labelled 
streptavidin was allowed to bind to biotinylated MMP 
antibodies present on microspheres. Microspheres 
were then loaded into a LABScanTM 100 analyser, which 
quantifies the amount of phycoerythrin fluorescence 
present on each of the distinct microspheres. The me-
dian fluorescence intensity was used for subsequent 
calculations.
Statistical analysis
Pearson and Spearman tests were used to evaluate 
the BMI correlation with age, and hormone and me-
talloproteinases levels. The analysis of the results of 
metalloproteinase concentrations according to BMI 
was performed by the Kruskal-Wallis test. Statistical 
significance was considered when p < 0.05. 
Results
The mean age of study group was 33 (± 5.45) years with 
a mean BMI of 24.55 (± 5.55) kg/m2. The mean serum 
oestradiol concentration was 102.16 (± 84.03) pg/ml and 
progesterone concentration 4.88 (± 5.58) ng/ml. Mean 
BMI in the group of normal weight women was 21.6 
(± 1.89) kg/m2, in overweight 26.71 (± 1.32) kg/m2, and 
in obese 34.35 (± 6.81) kg/m2. 
The mean concentrations of MMPs were: MMP-1 
120.75 (± 91.70) pg/ml, MMP-8 82.90 (± 64.14) pg/ml, 
MMP-13 4.90 (± 3.71) pg/ml MMP-3 558.61 (± 216.73) 
pg/ml, MMP-7 243.33 (± 118.21) pg/ml, MMP-9 1790.29 
(± 2066.08) pg/ml, MMP-12 15.22 (± 6.47) pg/ml. Bio-
chemical markings were done in two groups, as pre-
viosly described (32 patients in day 4–6 and 20 patients 
in day 21–22). Complete data are presented in Table I. 
Descriptive statistics of participants are presented in 
Table I. 
The results show that BMI was not correlated with 
age. A statistically significant correlation was found be-
tween BMI and: MMP-7 (p < 0.05), MMP-8 (p < 0.001), 
MMP-9 (p < 0.01), and MMP-12 (p < 0.05). The coef-
ficient (r) indicates that this interdependence can be 
defined as mean and positive (Fig. 1). In contrast, there 
was no correlation between previously mentioned 
MMPs and oestradiol or progesterone concentrations 
or the age of the examined women. The analysis of 
BMI correlations with age and concentration of the 
examined metalloproteinases is presented in Table II.
Table I. Clinical characteristics, hormones, and metalloproteinase levels of the study group
Tabela I. Charakterystyka kliniczna oraz stężenia hormonów i metaloproteinaz u uczestników badania
Descriptive statistics
Covariates Count Mean Median SD
Age (years) 52 33.02 34.00 5.45
BMI [kg/m2] 52 24.55 22.98 5.55
Oestradiol [pg/ml] 52 102.16 79.57 84.03
Progesterone [ng/ml] 52 4.88 1.77 5.58
Group BMI BMI = 18.8–24.9 [kg/m2] 34 21.60 21.75 1.89
BMI = 25.0–29.9 [kg/m2] 10 26.71 26.97 1.32
BMI ≥ 30 [kg/m2] 8 34.35 31.97 6.81
Collagenase MMP-1 [pg/ml] 51 120.75 92.43 91.70
MMP-8 [pg/ml] 51 82.90 75.69 64.14
MMP-13 [pg/ml] 51 4.90 4.07 3.71
Stromelysin MMP-3 [pg/ml] 51 558.61 512.07 216.73
Matrilysin MMP-7 [pg/ml] 51 243.33 218.06 118.21
Gelatinase MMP-9 [pg/ml] 51 1790.29 750.42 2066.08
Metalloelastase MMP-12 [pg/ml] 51 15.22 13.81 6.47
SD — standard deviation; BMI — body mass index; MMP — matrix metalloproteinase
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Figure 1. MMPs serum concentration versus body mass index (BMI). Pearson and Spearman rank correlation
Rycina 1. Stężenie MMP w surowicy a wartość wskaźnika masy ciała (BMI). Korelacja Pearsona i korelacja rang Spearmana
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Additionally, serum concentration of each of MMP 
was compared between the normoweight group 
(BMI-1) and the overweight group (BMI-2 and -3) 
using Kruskal-Wallis test (Fig. 2). MMP-7, MMP-8, 
MMP-9, MMP-12, and MMP-13 concentrations dif-
fered statistically significantly (p < 0.05) between these 
subgroups. The greatest differences were between the 
BMI-1 and BMI-3 group (Table III). MMP-1 and MMP-3 
concentrations did not differ significantly in the studied 
subgroups. 
Discussion
The presented study reached its established aim by 
confirming the positive correlation between MMP-7, 
MMP-8, MMP-9, MMP-12, and MMP-13 levels and BMI. 
Significantly higher concentrations of MMP-7, MMP-8, 
MMP-9, MMP-12, and MMP-13 were found especially 
in obese women compared to lean controls. In healthy, 
regularly menstruating, premenopausal women MMPs 
in blood did not correlate with oestradiol and proges-
terone concentrations. 
MMP-1
MMP-1 is linked to the development of atherosclero-
sis. It is responsible for collagen degradation in the 
vascular wall, and it influences platelet activation 
[15, 16]. The lack of correlation between serum MMP-1 
and BMI was probably due to the fact that the study 
was conducted in healthy women, without vascular 
dysfunction. 
Table II. Correlation between BMI, age, and MMPs serum 
concentration in the study group
Tabela II. Korelacja między BMI, wiekiem a stężeniem MMP 
w badanej grupie
Pearson correlation r p-value
Age (years) & BMI [kg/m2] 0.10 0.487
MMP-1 [pg/ml] & BMI [kg/m2] –0.27 0.057
MMP-8 [pg/ml] & BMI [kg/m2] 0.47 < 0.001
MMP-13 [pg/ml] & BMI [kg/m2] 0.14 0.322
MMP-3 [pg/ml] & BMI [kg/m2] 0.27 0.053
MMP-7 [pg/ml] & BMI [kg/m2] 0.37 0.007
MMP-9 [pg/ml] & BMI [kg/m2] 0.48 < 0.001
MMP-12 [pg/ml] & BMI [kg/m2] 0.41 0.003
BMI — body mass index; MMP — matrix metalloproteinase
Figure 2. MMPs serum concentration in three subgroups of women. Kruskal-Wallis test
Rycina 2. Stężenie MMP w surowicy w trzech podgrupach kobiet. Test Kruskala-Wallisa
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MMP-3
It was not found that the presence of MMP-3 in the 
blood was influenced by body weight or oestradiol 
and progesterone concentrations in our study. Prob-
ably because MMP-3 is secreted only in a state of se-
vere illness. Previous studies have shown the role of 
MMP-3 in the activation of gelatinase-A (MMP-2) and 
gelatinase-B (MMP-9) in the wall of damaged vessels 
[17]. The importance of MMP-3 has been demonstrated 
in the pathogenesis of heart failure [18], development 
of lung diseases [19], and rheumatoid arthritis [20]. In 
these conditions MMP-3 levels were elevated both in 
the affected tissue and in serum. 
MMP-7
Our research, according to our best knowledge, is the 
first clinical study that shows the association of obe-
sity and MMP-7 level. This finding may explain the 
significance of excess body weight in the development 
of atherosclerotic disease. Substrates for MMP-7 are:
 — apolipoprotein C-II (apoC-II), which is cofactor of 
lipoprotein lipase (LPL) and a component of very 
low-density lipoproteins and chylomicrons;
 — apolipoprotein A-IV (apoA-IV) [21]. 
Cleavage of apoC-II significantly lowers LPL ac-
tivity, resulting in hydrolysis of triglycerides in the 
blood and transfer of fatty acids to tissues. Cleavage of 
apoA-IV mediated by MMP-7 results in loss of intrinsic 
anti-oxidant activity and has pathological implications 
in the development of hyperlipidaemia and athero-
sclerosis [21]. 
MMP-8
MMP-8 (neutrophil collagenase) is involved in the 
pathogenesis of chronic inflammatory disorders, such 
as cardiovascular diseases, lung diseases, and cancer 
[22]. Aquilante et al. demonstrated higher serum MMP-8 
levels in patients with metabolic syndrome even in the 
absence of cardiovascular disease and diabetes [23]. 
The results of our study indicate a positive correla-
tion between serum MMP-8 and BMI. MMP-8 serum 
concentration in overweight women was significantly 
higher than those with normal body weight. However, 
the opposite results were shown by Andrade et al. [9]. 
He explained that the decrease of plasma MMP-8 con-
centration was by mechanisms not related to neutro-
phil activation, such as negative regulation of MMP-8 
expression by transforming growth factor beta 1. The 
authors also suggest that fatty tissue may not synthesise 
MMP-8 in such quantities as to be detected in the blood, 
which is contrary to our findings. 
MMP-9
MMP-9 is the major determinant of collagen degrada-
tion. It is the most commonly studied enzyme so far. 
The results of our study confirm the findings of other 
authors, who showed higher MMP-9 levels in obese 
compared to lean women [9, 24]. Adipose tissue is 
an important key regulator of adipocyte differentia-
tion [10]. The increase in MMP-9 circulating level in 
the population aged over 45 years, even without signs 
of coronary artery disease, is correlated with increased 
cardiovascular risk [25]. 
MMP-12
MMP-12 concentration was positively correlated with 
BMI in the osteochondral unit and adipose tissue [26]. 
In adipose tissue it is produced by macrophages and 
Table III. Results of MMPs serum concentration in three 
subgroups of patients: BMI-1 with BMI ≤ 24.9 kg/m2, BMI-2 
with BMI 25–29.9 kg/m2, and BMI-3 with BMI ≥ 30 kg/m2
Tabela III. Wyniki badania stężenia MMP w trzech 
podgrupach pacjentek: BMI-1 z BMI ≤ 24.9 kg/m2, BMI-2 
z BMI 25–29.9 kg/m2 i BMI-3 z BMI ≥ 30 kg/m2
Subgroups BMI-1  vs. BMI-2
BMI-2  
vs. BMI-3
BMI-1  
vs. BMI-3
MMP-1 
concentration Kruskal-Wallis test: H = 1.61 p = 0.431
Z 0.13 0.99 1.29
p-value 1.009 0.999 0.599
MMP-3 
concentration Kruskal-Wallis test: H = 4.05, p = 0.121
Z 0.98 2.00 1.51
p-value 0.988 0.136 0.391
MMP-7 
concentration Kruskal-Wallis test: H = 6.35, p = 0.042
Z 0.18 1.93 2.49
p-value 1.000 0.160 0.038
MMP-8 
concentration Kruskal-Wallis test: H = 9.43, p = 0.009
Z 0.09 2.44 3.02
p-value 1.000 0.044 0.008
MMP-9 
concentration Kruskal-Wallis test: H = 11.36, p = 0.003
Z 1.53 1.53 3.26
p-value 0.379 0.366 0.003
MMP-12 
concentration Kruskal-Wallis test: H = 6.31, p = 0.043
Z 0.34 1.82 2.50
p-value 1.000 0.205 0.037
MMP-13 
concentration Kruskal-Wallis test: H = 8.85, p = 0.012
Z 0.59 2.02 2.97
p-value 1.000 0.129 0.009
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preadipocytes [27]. It has also been found in atheroscle-
rotic plaque, where it is responsible for the degradation 
of elastic fibres [28]. Our results indicate that also the 
blood concentration of MMP-12 is statistically higher 
in overweight and obese women compared to lean 
women. However, whether this correlation is the result 
of increased production in adipose tissue or changes in 
vascular walls requires further research. 
MMP-13
MMP-13 is more efficient in cleaving type II collagen 
than types I and III [29]. The positive correlation be-
tween BMI and MMP-13 in our study indicates that 
obesity is an independent factor that increases blood 
MMP-13 levels. In obese people adipose tissue may be 
the source of excessive MMP-13 production. MMP-13 
inhibitors have been shown to inhibit adipogenesis 
and prevent diet-induced obesity in mice [30]. In hu-
mans, increased levels of MMP-13 have been reported 
with atheroma and developing heart disease [31]. This 
finding could lead to developing new ways of tackling 
obesity in humans. 
There is no relationship between the concentration 
of this MMP and the concentration of oestradiol and 
progesterone in the blood. A strong link between oestra-
diol and age and MMP-13 concentrations was reported 
only in murine skin squamous cell carcinoma cases [32].
Conclusions
In conclusion, despite the small number of subjects 
included in the study, we found significant differences 
in MMP-7, MMP-8, MMP-9, MMP-12, and MMP-13 
serum concentrations between lean and overweight 
women. Those findings suggest that these MMPs may 
play a role in the pathogenesis of body mass-related 
diseases. However, the exact mechanisms are still 
unclear, and further studies are needed to clarify the 
problem.
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